Novo Nordisk is rolling out a tablet version of Ozempic (semaglutide) across the United States starting May 4, bringing a well-known injectable treatment into a pill format. It sounds simple—same drug, different delivery—but in reality, getting a peptide-based therapy into an oral form has been a long-standing scientific hurdle, so this is… kind of a big deal. For years, Ozempic has been associated with weekly injections, widely prescribed for adults with Type 2 diabetes not just to control blood sugar but also to reduce the risk of serious cardiovascular events like heart attacks and strokes.

Tempus AI, Inc. (NASDAQ: TEM) is moving deeper into the clinical workflow layer with the launch of an automated update service designed to keep cancer care aligned with the latest medical guidance in real time. The system introduces what the company describes as an “active follow-up” model, where patients remain continuously monitored after their initial genomic profiling rather than relying on a static report that can quickly lose relevance. At the center of this approach is an integrated workflow within Tempus’ physician platform, Hub.

The economics of healthcare hiring have always had a strange flaw baked into them. Systems spend aggressively to attract talent, then act surprised when that same talent leaves once the incentives expire. What Clasp is doing—backed now by a $20 million Series B—isn’t just another HR-tech tweak. It’s an attempt to rewrite the incentive structure entirely, shifting the focus from recruitment spikes to long-term workforce stability. At the center of Clasp’s model is a concept borrowed from the military: early commitment.

Doctronic, an AI-native healthcare platform legally authorized to practice medicine in the United States, has announced a $40 million Series B funding round co-led by Abstract and Lightspeed Venture Partners, with participation from Union Square Ventures, Seven Stars, Mantis, and Tusk Ventures. The new financing brings total funding to more than $65 million, marking the company’s third round in less than 12 months and reinforcing investor confidence in its rapidly scaling model.